Kedalion Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Kedalion Therapeutics was a clinical-stage, venture-funded ophthalmic drug company based in Menlo Park, California, founded in 2015 by Chairman and CEO Mark Blumenkranz and CTO Ehud Ivri. Its proprietary AcuStream platform technology delivered topical drugs to the eye in a precise, accurate manner, enabling comparable efficacy with an 80% reduction in dose compared to standard eye drops, along with an improved side-effect profile.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Kedalion was founded in Menlo Park as a venture-backed ophthalmic drug company and raised an $800,000 seed round.
- Series A
The company raised a $5 million Series A to develop its AcuStream topical eye drug delivery platform.
- Series B and option-to-acquire agreement
Kedalion secured Series B funding and signed an option-to-acquire agreement with Novartis Innovative Medicines.
- Acquisition completed
A merger/acquisition transaction completed in June 2022 valued at $49 million.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.